|
Ascletis Pharma Inc. is a biotechnology company engaged in the research, development, and production of pharmaceutical products, with a primary focus on therapeutics for metabolic diseases. The company utilizes proprietary technologies, including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), the Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT), to develop small molecule and peptide drug candidates. Its pipeline includes lead programs such as ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes, and various fixed-dose combinations involving GLP-1R, GIPR, and amylin receptor agonists. The company also explores indications in immune diseases and other exploratory areas. Ascletis Pharma Inc. is listed on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage ascletis.com |
| Sector Healthcare | IR page ascletis.com | |
|
Tags
metabolic diseases, glp-1r agonists, peptide therapeutics, small molecules, obesity, diabetes, drug discovery, oral formulations, ASC30, ASC30_48FDC, ASC30_48_39FDC, ASC39, ASC30_39FDC, ASC36, ASC35, ASC36_35FDC, ASC37, ASC36_37FDC, AISBDD, ULAP, POTENT, Ascletis BioScience, Ascletis Pharmaceuticals, Ascletis Pharma (China), Ascletis Biopharma, Ascletis Xinnuo Medicine, Gannex Pharma, Gannex LLC, ASCLETIS (AUSTRALIA) PTY LTD, SoundRidge Pharmaceuticals (Hong Kong) Co. Limited, AP11 Limited, PowerTree
|
Press page ascletis.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 4.62B |
| Market cap (USD) | $ 588.78M |
| P/E | -6.64 |
| PEG | — |
| P/BV | 1.60 |
| P/S | — |
| P/OCF | -6.87 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.10% |
| Returns | |
|---|---|
| ROE | -18.5% |
| ROI | -18.6% |
| ROIC | -13.9% |
| Profit margin | -17,745.6% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -75.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.